MDNAF — Medicenna Therapeutics Corp.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1807983 ·
Last close
$0.26
Market Cap
$24.00M
52W High
$0.53
52W Low
$0.25
ADV30
80,540
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,822,000 | -4,234,000 | 8,454,000 | 6,251,000 | 5,972,000 |
| Dec 2025 | 0 | — | -5,616,000 | -4,364,000 | 13,065,000 | 10,614,000 | 6,853,000 |
| Sep 2025 | 0 | — | -5,470,000 | -4,883,000 | 18,041,000 | 15,748,000 | 7,799,000 |
| Jun 2025 | 0 | — | -5,509,000 | -4,928,000 | 22,770,000 | 20,459,000 | 8,129,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-18,444,000
Investing CF
$2,000
Financing CF
$-18,000
CapEx
$-2,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.24
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-132,427,000
Inventory
—
Receivables
$1,465,000
ST Investments
—
EBIT TTM
$-22,314,000
Pretax Income TTM
$-12,988,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | -22,417,000 | -18,409,000 | 8,454,000 | 5,972,000 | — | -17,923,000 |
| Mar 2025 | 0 | -20,406,000 | -11,805,000 | 28,382,000 | 9,287,000 | — | -16,492,000 |
| Mar 2024 | 0 | -18,674,000 | -25,466,000 | 19,134,000 | 13,943,000 | — | -16,260,000 |
| Mar 2023 | 0 | -16,303,000 | -10,048,000 | 36,446,000 | 6,960,000 | — | -12,657,000 |
| Mar 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.17
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AYTU | AYTU BIOPHARMA, INC | $24.15M | $2.25 | — |
| SKYE | Skye Bioscience, Inc. | $24.25M | $0.69 | — |
| AKTX | Akari Therapeutics Plc | $24.30M | $13.88 | — |
| ATOS | ATOSSA THERAPEUTICS, INC. | $23.64M | $2.37 | — |
| TXMD | TherapeuticsMD, Inc. | $23.15M | $2.00 | — |
News headlines (Yahoo Finance, 1h cache)
Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights
2026-06-26 12:45 · Yahoo
Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
2026-06-11 11:00 · Yahoo
Medicenna Therapeutics Provides MDNA11 Update
2026-06-03 13:55 · Yahoo
Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
2026-06-03 11:00 · Yahoo
Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs
2026-05-28 13:10 · Yahoo
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
2026-05-22 11:00 · Yahoo
Medicenna Announces the Finalization of the Terms of its Public Offering of Securities
2026-05-19 11:00 · Yahoo
Medicenna Announces the Launch of a Marketed Public Offering of Securities
2026-05-13 20:01 · Yahoo
Medicenna Says First Patient Dosed in NEO-CYT Study
2026-05-12 12:10 · Yahoo
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
2026-05-12 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.